View details of this raise on Seedstage

Jupiter, FL

Developing a novel therapy for osteoarthritis using engineered proteins.

• Innovative Therapy: CYT-108 is a genetically-engineered protein designed to treat osteoarthritis.
• Extensive Research: Partnered with Stanford and Scripps, Cytonics holds 26 patents worldwide.
• Clinical Progress: Over 10,000 patients treated with first-generation therapy.
• Strategic Partnerships: Collaborations with athletic figures to enhance credibility and reach.
• Focused Development: Aims to halt and repair joint damage at the molecular level.

Cytonics is developing a novel therapy for osteoarthritis (OA), a condition affecting over 500 million people worldwide. The company is working on CYT-108, a genetically-engineered variant of the Alpha-2-Macroglobulin protein, designed to offer protective and regenerative effects to joint tissues. This therapy aims to halt and repair joint damage at the molecular level, addressing the complex nature of OA that current treatments fail to manage effectively.

The company has already treated over 10,000 patients with its first-generation therapy and holds 26 patents worldwide. Partnering with leading research institutions like Stanford and Scripps, Cytonics is advancing its clinical trials to bring this innovative treatment to market. The company is also strategically partnered with figures in athletics to enhance its reach and credibility. Cytonics’ approach leverages the therapeutic power of A2M by delivering high concentrations directly into arthritic joints, aiming to reduce inflammation and stimulate cartilage regrowth.

Company Info

Cytonics is developing CYT-108, a genetically-engineered therapy for osteoarthritis, aiming to halt and repair joint damage.

Cytonics is focused on developing innovative therapies for osteoarthritis, a condition affecting over 500 million people worldwide. The company is pioneering a disease-modifying treatment called CYT-108, which is a genetically-engineered variant of the natural Alpha-2-Macroglobulin protein. This therapy aims to provide protective and regenerative effects to joint tissues, potentially halting and repairing joint damage at the molecular level.

The company has already treated over 10,000 patients with its first-generation therapy and holds more than 25 patents globally. Partnering with leading research institutions like Stanford and Scripps, Cytonics is advancing its clinical trials to bring this next-generation therapy to market. By focusing on intra-articular delivery, CYT-108 is designed to maximize concentration and minimize off-target effects, offering a promising solution to a complex and widespread health issue.